Cross-talk between estradiol receptor and EGFR/IGF-IR signaling pathways in estrogen-responsive breast cancers: Focus on the role and impact of proteoglycans

Matrix Biology

Volumn 35, Issue , 2014, Pages 182-193

  Skandalis, Spyros S ^a   Afratis, Nikolaos ^a   Smirlaki, Gianna ^a   Nikitovic, Dragana ^b   Theocharis, Achilleas D ^a   Tzanakakis, George N ^b   Karamanos, Nikos K ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

Cell signaling; Epidermal growth factor receptor; Estradiol; Estrogen receptors; Extracellular matrix; Insulin like growth factor receptor; Proteoglycans

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ESTRADIOL RECEPTOR; FIBRONECTIN; GELATINASE A; GELATINASE B; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; HYALURONIC ACID; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; LUMICAN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEOGLYCAN; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; SOMATOMEDIN RECEPTOR;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER GROWTH; CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURFACE; DEREGULATION; GENE EXPRESSION; HORMONAL THERAPY; HUMAN; MACROMOLECULE; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY; ANIMAL; BIOLOGICAL MODEL; BREAST TUMOR; FEMALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; MODELS, BIOLOGICAL; PROTEOGLYCANS; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTRADIOL; RECEPTORS, SOMATOMEDIN; SIGNAL TRANSDUCTION;

EID: 84901409424     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2013.09.002     Document Type: Article

References (187)

1. Acconcia F., Kumar R. Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett. 2006, 238:1-14.
2. Adams T.E., McKern N.M., Ward C.W. Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor. Growth Factors 2004, 22:89-95.
3. Adany R., Heimer R., Caterson B., Sorrell J.M., Iozzo R.V. Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. Hypomethylation of PG-40 gene correlates with increased PG-40 content and mRNA levels. J. Biol. Chem. 1990, 265:11389-11396.
4. Afratis N., Gialeli C., Nikitovic D., Tsegenidis T., Karousou E., Theocharis A.D., Pavao M.S., Tzanakakis G.N., Karamanos N.K. Glycosaminoglycans: key players in cancer cell biology and treatment. FEBS J. 2012, 279:1177-1197.
5. Alexaki V.I., Charalampopoulos I., Kampa M., Vassalou H., Theodoropoulos P., Stathopoulos E.N., Hatzoglou A., Gravanis A., Castanas E. Estrogen exerts neuroprotective effects via membrane estrogen receptors and rapid Akt/NOS activation. FASEB J. 2004, 18:1594-1596.
6. Alexander C.M., Reichsman F., Hinkes M.T., Lincecum J., Becker K.A., Cumberledge S., Bernfield M. Syndecan1 is required for Wnt-induced mammary tumorigenesis in mice. Nat. Genet. 2000, 25(3):329-332.
7. Ali S., Coombes R.C. Estrogen receptor alpha in human breast cancer: occurrence and significance. J. Mammary Gland Biol. Neoplasia 2000, 5:271-281.
8. Allred D.C. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod. Pathol. 2010, 23(Suppl. 2):S52-S59.
9. Allred D.C., Mohsin S.K. Biological features of premalignant disease in the human breast. J. Mammary Gland Biol. Neoplasia 2000, 5:351-364.
10. Ankrapp D.P., Bennett J.M., Haslam S.Z. Role of epidermal growth factor in the acquisition of ovarian steroid hormone responsiveness in the normal mouse mammary gland. J. Cell. Physiol. 1998, 174:251-260.
11. Ascenzi P., Bocedi A., Marino M. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol. Aspects Med. 2006, 27:299-402.
12. Auvinen P., Tammi R., Parkkinen J., Tammi M., Agren U., Johansson R., Hirvikoski P., Eskelinen M., Kosma V.M. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am. J. Pathol. 2000, 156:529-536.
13. Azios N.G., Dharmawardhane S.F. Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer cells. Neoplasia 2005, 7:128-140.
14. Barash U., Cohen-Kaplan V., Dowek I., Sanderson R.D., Ilan N., Vlodavsky I. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J. 2010, 277:3890-3903.
15. Barbareschi M., Maisonneuve P., Aldovini D., Cangi M.G., Pecciarini L., Angelo Mauri F., Veronese S., Caffo O., Lucenti A., Palma P.D., Galligioni E., Doglioni C. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 2003, 98:474-483.
16. Baserga R., Peruzzi F., Reiss K. The IGF-1 receptor in cancer biology. Int. J. Cancer 2003, 107:873-877.
17. Beauvais D.M., Rapraeger A.C. Syndecan-1-mediated cell spreading requires signaling by alphavbeta3 integrins in human breast carcinoma cells. Exp. Cell Res. 2003, 286:219-232.
18. Beauvais D.M., Rapraeger A.C. Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation. J. Cell Sci. 2010, 123:3796-3807.
19. Beauvais D.M., Burbach B.J., Rapraeger A.C. The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells. J. Cell Biol. 2004, 167:171-181.
20. Beauvais D.M., Ell B.J., McWhorter A.R., Rapraeger A.C. Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J. Exp. Med. 2009, 206:691-705.
21. Berdiaki A., Nikitovic D., Tsatsakis A., Katonis P., Karamanos N.K., Tzanakakis G.N. bFGF induces changes in hyaluronan synthase and hyaluronidase isoform expression and modulates the migration capacity of fibrosarcoma cells. Biochim. Biophys. Acta 2009, 1790:1258-1265.
22. Bernert B., Porsch H., Heldin P. Hyaluronan synthase 2 (HAS2) promotes breast cancer cell invasion by suppression of tissue metalloproteinase inhibitor 1 (TIMP-1). J. Biol. Chem. 2011, 286:42349-42359.
23. Bernfield M., Kokenyesi R., Kato M., Hinkes M.T., Spring J., Gallo R.L., Lose E.J. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu. Rev. Cell Biol. 1992, 8:365-393.
24. Bostrom P., Sainio A., Kakko T., Savontaus M., Soderstrom M., Jarvelainen H. Localization of decorin gene expression in normal human breast tissue and in benign and malignant tumors of the human breast. Histochem. Cell Biol. 2013, 139:161-171.
25. Bourguignon L.Y., Wong G., Earle C.A., Xia W. Interaction of low molecular weight hyaluronan with CD44 and toll-like receptors promotes the actin filament-associated protein 110-actin binding and MyD88-NFkappaB signaling leading to proinflammatory cytokine/chemokine production and breast tumor invasion. Cytoskeleton (Hoboken) 2011, 68:671-693.
26. Bredin C.G., Liu Z., Klominek J. Growth factor-enhanced expression and activity of matrix metalloproteases in human non-small cell lung cancer cell lines. Anticancer. Res. 2003, 23:4877-4884.
27. Brezillon S., Venteo L., Ramont L., D'Onofrio M.F., Perreau C., Pluot M., Maquart F.X., Wegrowski Y. Expression of lumican, a small leucine-rich proteoglycan with antitumour activity, in human malignant melanoma. Clin. Exp. Dermatol. 2007, 32:405-416.
28. Brezillon S., Zeltz C., Schneider L., Terryn C., Vuillermoz B., Ramont L., Perrau C., Pluot M., Diebold M.D., Radwanska A., Malicka-Blaszkiewicz M., Maquart F.X., Wegrowski Y. Lumican inhibits B16F1 melanoma cell lung metastasis. J. Physiol. Pharmacol. 2009, 60(Suppl. 4):15-22.
29. Cai W., Chen X. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med. Chem. 2006, 6:407-428.
30. Cano-Gauci D.F., Song H.H., Yang H., McKerlie C., Choo B., Shi W., Pullano R., Piscione T.D., Grisaru S., Soon S., Sedlackova L., Tanswell A.K., Mak T.W., Yeger H., Lockwood G.A., Rosenblum N.D., Filmus J. Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome. J. Cell Biol. 1999, 146:255-264.
31. Carelli S., Di Giulio A.M., Paratore S., Bosari S., Gorio A. Degradation of insulin-like growth factor-I receptor occurs via ubiquitin-proteasome pathway in human lung cancer cells. J. Cell. Physiol. 2006, 208:354-362.
32. Chen Y., Scully M., Dawson G., Goodwin C., Xia M., Lu X., Kakkar A. Perturbation of the heparin/heparin-sulfate interactome of human breast cancer cells modulates pro-tumourigenic effects associated with PI3K/Akt and MAPK/ERK signalling. Thromb. Haemost. 2013, 109:1148-1157.
33. Cheskis B.J. Regulation of cell signalling cascades by steroid hormones. J. Cell. Biochem. 2004, 93:20-27.
34. Clarke R.B., Howell A., Anderson E. Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: analysis of the relationship between estrogen-induced proliferation and progesterone receptor expression. Breast Cancer Res. Treat. 1997, 45:121-133.
35. Cohen I., Maly B., Simon I., Meirovitz A., Pikarsky E., Zcharia E., Peretz T., Vlodavsky I., Elkin M. Tamoxifen induces heparanase expression in estrogen receptor-positive breast cancer. Clin. Cancer Res. 2007, 13(14):4069-4077.
36. Cooney C.A., Jousheghany F., Yao-Borengasser A., Phanavanh B., Gomes T., Kieber-Emmons A.M., Siegel E.R., Suva L.J., Ferrone S., Kieber-Emmons T., Monzavi-Karbassi B. Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. Breast Cancer Res. 2011, 13:R58.
37. Csordas G., Santra M., Reed C.C., Eichstetter I., McQuillan D.J., Gross D., Nugent M.A., Hajnoczky G., Iozzo R.V. Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J. Biol. Chem. 2000, 275:32879-32887.
38. Curtis S.W., Washburn T., Sewall C., DiAugustine R., Lindzey J., Couse J.F., Korach K.S. Physiological coupling of growth factor and steroid receptor signaling pathways: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:12626-12630.
39. de Blaquiere G.E., May F.E., Westley B.R. Increased expression of both insulin receptor substrates 1 and 2 confers increased sensitivity to IGF-1 stimulated cell migration. Endocrinol. Relat. Cancer 2009, 16:635-647.
40. De Luca A., Santra M., Baldi A., Giordano A., Iozzo R.V. Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J. Biol. Chem. 1996, 271:18961-18965.
41. Dickinson L.E., Ho C.C., Wang G.M., Stebe K.J., Gerecht S. Functional surfaces for high-resolution analysis of cancer cell interactions on exogenous hyaluronic acid. Biomaterials 2010, 31:5472-5478.
42. Dickson R.B., Lippman M.E. Control of human breast cancer by estrogen, growth factors, and oncogenes. Cancer Treat. Res. 1988, 40:119-165.
43. Du W.W., Yang B.B., Shatseva T.A., Yang B.L., Deng Z., Shan S.W., Lee D.Y., Seth A., Yee A.J. Versican G3 promotes mouse mammary tumor cell growth, migration, and metastasis by influencing EGF receptor signaling. PLoS One 2010, 5:e13828.
44. Du W.W., Yang B.B., Yang B.L., Deng Z., Fang L., Shan S.W., Jeyapalan Z., Zhang Y., Seth A., Yee A.J. Versican G3 domain modulates breast cancer cell apoptosis: a mechanism for breast cancer cell response to chemotherapy and EGFR therapy. PLoS One 2011, 6:e26396.
45. Du W.W., Fang L., Yang W., Sheng W., Zhang Y., Seth A., Yang B.B., Yee A.J. The role of versican G3 domain in regulating breast cancer cell motility including effects on osteoblast cell growth and differentiation in vitro - evaluation towards understanding breast cancer cell bone metastasis. BMC Cancer 2012, 12:341.
46. Du W.W., Fang L., Yang X., Sheng W., Yang B.L., Seth A., Zhang Y., Yang B.B., Yee A.J. The role of versican in modulating breast cancer cell self-renewal. Mol. Cancer Res. 2013, 11:443-455.
47. Du Y., Liu H., He Y., Liu Y., Yang C., Zhou M., Wang W., Cui L., Hu J., Gao F. The interaction between LYVE-1 with hyaluronan on the cell surface may play a role in the diversity of adhesion to cancer cells. PLoS One 2013, 8:e63463.
48. Elkin M., Cohen I., Zcharia E., Orgel A., Guatta-Rangini Z., Peretz T., Vlodavsky I., Kleinman H.K. Regulation of heparanase gene expression by estrogen in breast cancer. Cancer Res. 2003, 63(24):8821-8826.
49. Erickson A.C., Barcellos-Hoff M.H. The not-so innocent bystander: the microenvironment as a therapeutic target in cancer. Expert. Opin. Ther. Targets 2003, 7:71-88.
50. Filmus J., Selleck S.B. Glypicans: proteoglycans with a surprise. J. Clin. Invest. 2001, 108:497-501.
51. Fisher B., Redmond C., Fisher E.R., Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J. Clin. Oncol. 1988, 6:1076-1087.
52. Fox E.M., Andrade J., Shupnik M.A. Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways. Steroids 2009, 74:622-627.
53. Fujii M., Yusa A., Yokoyama Y., Kokuryo T., Tsunoda N., Oda K., Nagino M., Ishimaru T., Shimoyama Y., Utsunomiya H., Iwata H., Itoh Y., Itoh J., Kannagi R., Kyogashima M. Cytoplasmic expression of the JM403 antigen GlcA-GlcNH3+ on heparan sulfate glycosaminoglycan in mammary carcinomas-a novel proliferative biomarker for breast cancers with high malignancy. Glycoconj. J. 2010, 27:661-672.
54. Gialeli C., Theocharis A.D., Karamanos N.K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011, 278:16-27.
55. Gonzalez A.D., Kaya M., Shi W., Song H., Testa J.R., Penn L.Z., Filmus J. OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. J. Cell Biol. 1998, 141:1407-1414.
56. Gu Y., Zhang S., Wu Q., Xu S., Cui Y., Yang Z., Zhao X., Sun B. Differential expression of decorin, EGFR and cyclin D1 during mammary gland carcinogenesis in TA2 mice with spontaneous breast cancer. J. Exp. Clin. Cancer Res. 2010, 29:6.
57. Hadler-Olsen E., Fadnes B., Sylte I., Uhlin-Hansen L., Winberg J.O. Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 2011, 278:28-45.
58. Hanstein B., Djahansouzi S., Dall P., Beckmann M.W., Bender H.G. Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer. Eur. J. Endocrinol. 2004, 150:243-255.
59. Hart S., Fischer O.M., Prenzel N., Zwick-Wallasch E., Schneider M., Hennighausen L., Ullrich A. GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways. Biol. Chem. 2005, 386:845-855.
60. Hassan H., Greve B., Pavao M.S., Kiesel L., Ibrahim S.A., Gotte M. Syndecan-1 modulates beta-integrin-dependent and interleukin-6-dependent functions in breast cancer cell adhesion, migration, and resistance to irradiation. FEBS J. 2013, 280:2216-2227.
61. Heldring N., Pike A., Andersson S., Matthews J., Cheng G., Hartman J., Tujague M., Strom A., Treuter E., Warner M., Gustafsson J.A. Estrogen receptors: how do they signal and what are their targets. Physiol. Rev. 2007, 87:905-931.
62. Helguero L.A., Faulds M.H., Gustafsson J.A., Haldosen L.A. Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 2005, 24:6605-6616.
63. Hsu E., Feghali-Bostwick C.A. Insulin-like growth factor-II is increased in systemic sclerosis-associated pulmonary fibrosis and contributes to the fibrotic process via Jun N-terminal kinase- and phosphatidylinositol-3 kinase-dependent pathways. Am. J. Pathol. 2008, 172:1580-1590.
64. Ibrahim S.A., Yip G.W., Stock C., Pan J.W., Neubauer C., Poeter M., Pupjalis D., Koo C.Y., Kelsch R., Schule R., Rescher U., Kiesel L., Gotte M. Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase- and E-cadherin-dependent mechanism. Int. J. Cancer 2012, 131:E884-E896.
65. Iozzo R.V. Matrix proteoglycans: from molecular design to cellular function. Annu. Rev. Biochem. 1998, 67:609-652.
66. Iozzo R.V., Karamanos N. Proteoglycans in health and disease: emerging concepts and future directions. FEBS J. 2010, 277:3863.
67. Iozzo R.V., Schaefer L. Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J. 2010, 277:3864-3875.
68. Iozzo R.V., Bolender R.P., Wight T.N. Proteoglycan changes in the intercellular matrix of human colon carcinoma: an integrated biochemical and stereologic analysis. Lab. Invest. 1982, 47:124-138.
69. Iozzo R.V., Moscatello D.K., McQuillan D.J., Eichstetter I. Decorin is a biological ligand for the epidermal growth factor receptor. J. Biol. Chem. 1999, 274:4489-4492.
70. Iozzo R.V., Buraschi S., Genua M., Xu S.Q., Solomides C.C., Peiper S.C., Gomella L.G., Owens R.C., Morrione A. Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling. J. Biol. Chem. 2011, 286:34712-34721.
71. Jacquemier J.D., Hassoun J., Torrente M., Martin P.M. Distribution of estrogen and progesterone receptors in healthy tissue adjacent to breast lesions at various stages-immunohistochemical study of 107 cases. Breast Cancer Res. Treat. 1990, 15:109-117.
72. Jensen E.V., Jordan V.C. The estrogen receptor: a model for molecular medicine. Clin. Cancer Res. 2003, 9:1980-1989.
73. Jojovic M., Delpech B., Prehm P., Schumacher U. Expression of hyaluronate and hyaluronate synthase in human primary tumours and their metastases in scid mice. Cancer Lett. 2002, 188:181-189.
74. Kahlert S., Nuedling S., van Eickels M., Vetter H., Meyer R., Grohe C. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J. Biol. Chem. 2000, 275:18447-18453.
75. Karamanos N.K., Linhardt R.J. Special issue: proteoglycans: signaling, targeting and therapeutics: introduction. FEBS J. 2013, 280:2119.
76. Karamanos N.K., Tzanakakis G.N. Glycosaminoglycans: from "cellular glue" to novel therapeutic agents. Curr. Opin. Pharmacol. 2012, 12:220-222.
77. Kelemen L.E., Couch F.J., Ahmed S., Dunning A.M., Pharoah P.D., Easton D.F., Fredericksen Z.S., Vierkant R.A., Pankratz V.S., Goode E.L., Scott C.G., Rider D.N., Wang X., Cerhan J.R., Vachon C.M. Genetic variation in stromal proteins decorin and lumican with breast cancer: investigations in two case-control studies. Breast Cancer Res. 2008, 10:R98.
78. Klijn J.G., Berns P.M., Schmitz P.I., Foekens J.A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr. Rev. 1992, 13:3-17.
79. Klotz D.M., Hewitt S.C., Ciana P., Raviscioni M., Lindzey J.K., Foley J., Maggi A., DiAugustine R.P., Korach K.S. Requirement of estrogen receptor-alpha in insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor cross-talk. J. Biol. Chem. 2002, 277:8531-8537.
80. Knowlden J.M., Hutcheson I.R., Barrow D., Gee J.M., Nicholson R.I. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 2005, 146:4609-4618.
81. Kolset S.O., Pejler G. Serglycin: a structural and functional chameleon with wide impact on immune cells. J. Immunol. 2011, 187:4927-4933.
82. Korpetinou A., Triantaphyllidou I.E., Giannopoulou E., et al. Aggressive breast cancer cells secrete serglycin, a potent inhibitor of complement system. FEBS J. 2011, 2787(Suppl. 1):419.
83. Korpetinou A., Milia-Argeiti E., Labropoulou V., Theocharis A. Serglycin: a novel player in the terrain of neoplasia. Extracellular Matrix: Pathobiology and Signaling 2012, 677-688. De Gruyter, Berlin. N.K. Karamanos (Ed.).
84. Kousidou O., Berdiaki A., Kletsas D., Zafiropoulos A., Theocharis A.D., Tzanakakis G.N., Karamanos N.K. Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells. Mol. Oncol. 2008, 2:223-232.
85. Kumar C.C., Malkowski M., Yin Z., Tanghetti E., Yaremko B., Nechuta T., Varner J., Liu M., Smith E.M., Neustadt B., Presta M., Armstrong L. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Res. 2001, 61:2232-2238.
86. Kung C.I., Chen C.Y., Yang C.C., Lin C.Y., Chen T.H., Wang H.S. Enhanced membrane-type 1 matrix metalloproteinase expression by hyaluronan oligosaccharides in breast cancer cells facilitates CD44 cleavage and tumor cell migration. Oncol. Rep. 2012, 28:1808-1814.
87. Lai J., Chien J., Staub J., Avula R., Greene E.L., Matthews T.A., Smith D.I., Kaufmann S.H., Roberts L.R., Shridhar V. Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J. Biol. Chem. 2003, 278:23107-23117.
88. Lai J.P., Chien J., Strome S.E., Staub J., Montoya D.P., Greene E.L., Smith D.I., Roberts L.R., Shridhar V. HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene 2004, 23:1439-1447.
89. Lanzino M., Morelli C., Garofalo C., Panno M.L., Mauro L., Ando S., Sisci D. Interaction between estrogen receptor alpha and insulin/IGF signaling in breast cancer. Curr. Cancer Drug Targets 2008, 8:597-610.
90. LaPierre D.P., Lee D.Y., Li S.Z., Xie Y.Z., Zhong L., Sheng W., Deng Z., Yang B.B. The ability of versican to simultaneously cause apoptotic resistance and sensitivity. Cancer Res. 2007, 67:4742-4750.
91. Lazennec G., Bresson D., Lucas A., Chauveau C., Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001, 142:4120-4130.
92. Lee A.V., Jackson J.G., Gooch J.L., Hilsenbeck S.G., Coronado-Heinsohn E., Osborne C.K., Yee D. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol. Endocrinol. 1999, 13:787-796.
93. Lee A.V., Gooch J.L., Oesterreich S., Guler R.L., Yee D. Insulin-like growth factor I-induced degradation of insulin receptor substrate 1 is mediated by the 26S proteasome and blocked by phosphatidylinositol 3'-kinase inhibition. Mol. Cell. Biol. 2000, 20:1489-1496.
94. Leivonen M., Lundin J., Nordling S., von Boguslawski K., Haglund C. Prognostic value of syndecan-1 expression in breast cancer. Oncology 2004, 67:11-18.
95. Lendorf M.E., Manon-Jensen T., Kronqvist P., Multhaupt H.A., Couchman J.R. Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma. J. Histochem. Cytochem. 2011, 59:615-629.
96. Leygue E., Snell L., Dotzlaw H., Hole K., Hiller-Hitchcock T., Roughley P.J., Watson P.H., Murphy L.C. Expression of lumican in human breast carcinoma. Cancer Res. 1998, 58:1348-1352.
97. Leygue E., Snell L., Dotzlaw H., Troup S., Hiller-Hitchcock T., Murphy L.C., Roughley P.J., Watson P.H. Lumican and decorin are differentially expressed in human breast carcinoma. J. Pathol. 2000, 192:313-320.
98. Li Y., Aoki T., Mori Y., Ahmad M., Miyamori H., Takino T., Sato H. Cleavage of lumican by membrane-type matrix metalloproteinase-1 abrogates this proteoglycan-mediated suppression of tumor cell colony formation in soft agar. Cancer Res. 2004, 64:7058-7064.
99. Li X.J., Ong C.K., Cao Y., Xiang Y.Q., Shao J.Y., Ooi A., Peng L.X., Lu W.H., Zhang Z., Petillo D., Qin L., Bao Y.N., Zheng F.J., Chia C.S., Iyer N.G., Kang T.B., Zeng Y.X., Soo K.C., Trent J.M., Teh B.T., Qian C.N. Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res. 2011, 71:3162-3172.
100. Liapis H., Flath A., Kitazawa S. Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagn. Mol. Pathol. 1996, 5:127-135.
101. Lofgren L., Sahlin L., Jiang S., Von Schoultz B., Fernstad R., Skoog L., Von Schoultz E. Expression of syndecan-1 in paired samples of normal and malignant breast tissue from postmenopausal women. Anticancer. Res. 2007, 27:3045-3050.
102. Lundstrom E., Sahlin L., Skoog L., Hagerstrom T., Svane G., Azavedo E., Sandelin K., von Schoultz B. Expression of syndecan-1 in histologically normal breast tissue from postmenopausal women with breast cancer according to mammographic density. Climacteric 2006, 9:277-282.
103. Maeda T., Alexander C.M., Friedl A. Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells. Cancer Res. 2004, 64:612-621.
104. Maeda T., Desouky J., Friedl A. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 2006, 25:1408-1412.
105. Manon-Jensen T., Multhaupt H.A., Couchman J.R. Mapping of matrix metalloproteinase cleavage sites on syndecan-1 and syndecan-4 ectodomains. FEBS J. 2013, 280:2320-2331.
106. Marotti J.D., Collins L.C., Hu R., Tamimi R.M. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod. Pathol. 2010, 23:197-204.
107. Matsuda K., Maruyama H., Guo F., Kleeff J., Itakura J., Matsumoto Y., Lander A.D., Korc M. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res. 2001, 61:5562-5569.
108. Mauro L., Salerno M., Panno M.L., Bellizzi D., Sisci D., Miglietta A., Surmacz E., Ando S. Estradiol increases IRS-1 gene expression and insulin signaling in breast cancer cells. Biochem. Biophys. Res. Commun. 2001, 288:685-689.
109. McDonnell D.P., Norris J.D. Connections and regulation of the human estrogen receptor. Science 2002, 296:1642-1644.
110. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19:6550-6565.
111. Misra S., Heldin P., Hascall V.C., Karamanos N.K., Skandalis S.S., Markwald R.R., Ghatak S. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J. 2011, 278:1429-1443.
112. Mitropoulou T.N., Tzanakakis G.N., Kletsas D., Kalofonos H.P., Karamanos N.K. Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. Int. J. Cancer 2003, 104:155-160.
113. Mitropoulou T.N., Theocharis A.D., Nikitovic D., Karamanos N.K., Tzanakakis G.N. IGF-I affects glycosaminoglycan/proteoglycan synthesis in breast cancer cells through tyrosine kinase-dependent and -independent pathways. Biochimie 2004, 86:251-259.
114. Montgomery N., Hill A., McFarlane S., Neisen J., O'Grady A., Conlon S., Jirstrom K., Kay E.W., Waugh D.J. CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activity. Breast Cancer Res. 2012, 14:R84.
115. Mook S., Van 't Veer L.J., Rutgers E.J., Ravdin P.M., van de Velde A.O., van Leeuwen F.E., Visser O., Schmidt M.K. Independent prognostic value of screen detection in invasive breast cancer. J. Natl. Cancer Inst. 2011, 103:585-597.
116. Morelli C., Garofalo C., Bartucci M., Surmacz E. Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells. Oncogene 2003, 22:4007-4016.
117. Moscatello D.K., Santra M., Mann D.M., McQuillan D.J., Wong A.J., Iozzo R.V. Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J. Clin. Invest. 1998, 101:406-412.
118. Mundhenke C., Meyer K., Drew S., Friedl A. Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas. Am. J. Pathol. 2002, 160:185-194.
119. Nara Y., Kato Y., Torii Y., Tsuji Y., Nakagaki S., Goto S., Isobe H., Nakashima N., Takeuchi J. Immunohistochemical localization of extracellular matrix components in human breast tumours with special reference to PG-M/versican. Histochem. J. 1997, 29:21-30.
120. Narita K., Chien J., Mullany S.A., Staub J., Qian X., Lingle W.L., Shridhar V. Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer. J. Biol. Chem. 2007, 282:14413-14420.
121. Nicholson R.I., Johnston S.R. Endocrine therapy-current benefits and limitations. Breast Cancer Res. Treat. 2005, 93(Suppl. 1):S3-S10.
122. Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer 2001, 37(Suppl. 4):S9-S15.
123. Niewiarowska J., Brezillon S., Sacewicz-Hofman I., Bednarek R., Maquart F.X., Malinowski M., Wiktorska M., Wegrowski Y., Cierniewski C.S. Lumican inhibits angiogenesis by interfering with alpha2beta1 receptor activity and downregulating MMP-14 expression. Thromb. Res. 2011, 128:452-457.
124. Nikitovic D., Tzanakakis G.N. Roles of sulfated and non-sulfated glycosaminoglycans in cancer growth and progression-therapeutic implications. Extracellular Matrix: Pathobiology and Signaling 2012, 66-83. De Gruyter, Berlin. N.K. Karamanos (Ed.).
125. Nikitovic D., Pratsinis H., Berdiaki A., Gialeli C., Kletsas D., Tzanakakis G.N. Growth factor signaling and extracellular matrix. Extracellular Matrix: Pathobiology and Signaling 2012, 742-762. De Gruyter, Berlin. N.K. Karamanos (Ed.).
126. Nikitovic D., Berdiaki A., Banos A., Tsatsakis A., Karamanos N.K., Tzanakakis G.N. Could growth factor-mediated extracellular matrix deposition and degradation offer the ground for directed pharmacological targeting in fibrosarcoma?. Curr. Med. Chem. 2013, 20:2868-2880.
127. Nikolova V., Koo C.Y., Ibrahim S.A., Wang Z., Spillmann D., Dreier R., Kelsch R., Fischgrabe J., Smollich M., Rossi L.H., Sibrowski W., Wulfing P., Kiesel L., Yip G.W., Gotte M. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 2009, 30:397-407.
128. Nilsson S., Makela S., Treuter E., Tujague M., Thomsen J., Andersson G., Enmark E., Pettersson K., Warner M., Gustafsson J.A. Mechanisms of estrogen action. Physiol. Rev. 2001, 81:1535-1565.
129. O'Regan R.M., Cisneros A., England G.M., MacGregor J.I., Muenzner H.D., Assikis V.J., Bilimoria M.M., Piette M., Dragan Y.P., Pitot H.C., Chatterton R., Jordan V.C. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J. Natl. Cancer Inst. 1998, 90:1552-1558.
130. Palyi-Krekk Z., Barok M., Kovacs T., Saya H., Nagano O., Szollosi J., Nagy P. EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44. Cancer Lett. 2008, 263:231-242.
131. Paruthiyil S., Parmar H., Kerekatte V., Cunha G.R., Firestone G.L., Leitman D.C. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 2004, 64:423-428.
132. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lonning P.E., Borresen-Dale A.L., Brown P.O., Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
133. Peters M.G., Farias E., Colombo L., Filmus J., Puricelli L., de Kier Bal, Joffe E. Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model. Breast Cancer Res. Treat. 2003, 80:221-232.
134. Peterson S.M., Iskenderian A., Cook L., Romashko A., Tobin K., Jones M., Norton A., Gomez-Yafal A., Heartlein M.W., Concino M.F., Liaw L., Martini P.G. Human sulfatase 2 inhibits in vivo tumor growth of MDA-MB-231 human breast cancer xenografts. BMC Cancer 2010, 10:427.
135. Pietras R.J. Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature. Breast J. 2003, 9:361-373.
136. Porsch H., Bernert B., Mehić M., Theocharis A.D., Heldin C.H., Heldin P. Efficient TGFβ-induced epithelial-mesenchymal transition depends on hyaluronan synthase HAS2. Oncogene 2012, (Oct 29). 10.1038/onc.2012.475.
137. Prenzel N., Zwick E., Leserer M., Ullrich A. Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification. Breast Cancer Res. 2000, 2:184-190.
138. Qian X.L., Li Y.Q., Yu B., Gu F., Liu F.F., Li W.D., Zhang X.M., Fu L. Syndecan binding protein (SDCBP) is overexpressed in estrogen receptor negative breast cancers, and is a potential promoter for tumor proliferation. PLoS One 2013, 8:e60046.
139. Ramani V.C., Purushothaman A., Stewart M.D., Thompson C.A., Vlodavsky I., Au J.L., Sanderson R.D. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J. 2013, 280(10):2294-2306.
140. Rapraeger A.C., Ell B.J., Roy M., Li X., Morrison O.R., Thomas G.M., Beauvais D.M. Vascular endothelial-cadherin stimulates syndecan-1-coupled insulin-like growth factor-1 receptor and cross-talk between alphaVbeta3 integrin and vascular endothelial growth factor receptor 2 at the onset of endothelial cell dissemination during angiogenesis. FEBS J. 2013, 280:2194-2206.
141. Reed C.C., Waterhouse A., Kirby S., Kay P., Owens R.T., McQuillan D.J., Iozzo R.V. Decorin prevents metastatic spreading of breast cancer. Oncogene 2005, 24:1104-1110.
142. Ricciardelli C., Brooks J.H., Suwiwat S., Sakko A.J., Mayne K., Raymond W.A., Seshadri R., LeBaron R.G., Horsfall D.J. Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin. Cancer Res. 2002, 8:1054-1060.
143. Richards R.G., DiAugustine R.P., Petrusz P., Clark G.C., Sebastian J. Estradiol stimulates tyrosine phosphorylation of the insulin-like growth factor-1 receptor and insulin receptor substrate-1 in the uterus. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:12002-12007.
144. Roskoski R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem. Biophys. Res. Commun. 2004, 319:1-11.
145. Santen R.J., Song R.X., Zhang Z., Yue W., Kumar R. Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. Clin. Cancer Res. 2004, 10:337S-345S.
146. Santra M., Mann D.M., Mercer E.W., Skorski T., Calabretta B., Iozzo R.V. Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J. Clin. Invest. 1997, 100:149-157.
147. Santra M., Reed C.C., Iozzo R.V. Decorin binds to a narrow region of the epidermal growth factor (EGF) receptor, partially overlapping but distinct from the EGF-binding epitope. J. Biol. Chem. 2002, 277:35671-35681.
148. Schaefer L., Schaefer R.M. Proteoglycans: from structural compounds to signaling molecules. Cell Tissue Res. 2010, 339:237-246.
149. Schick B.P. Serglycin proteoglycan deletion in mouse platelets: physiological effects and their implications for platelet contributions to thrombosis, inflammation, atherosclerosis, and metastasis. Prog. Mol. Biol. Transl. Sci. 2010, 93:235-287.
150. Shupnik M.A. Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. Oncogene 2004, 23:7979-7989.
151. Silva C.M., Shupnik M.A. Integration of steroid and growth factor pathways in breast cancer: focus on signal transducers and activators of transcription and their potential role in resistance. Mol. Endocrinol. 2007, 21:1499-1512.
152. Skandalis S.S., Labropoulou V.T., Ravazoula P., Likaki-Karatza E., Dobra K., Kalofonos H.P., Karamanos N.K., Theocharis A.D. Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-appearing microcalcifications in non-palpable breast carcinomas. BMC Cancer 2011, 11:314.
153. Skliris A., Happonen K.E., Terpos E., Labropoulou V., Børset M., Heinegård D., Blom A.M., Theocharis A.D. Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: implications for multiple myeloma. Eur. J. Immunol. 2011, 41:437-449.
154. Skliris A., Labropoulou V.T., Papachristou D.J., Aletras A., Karamanos N.K., Theocharis A.D. Cell-surface serglycin promotes adhesion of myeloma cells to collagen type I and affects the expression of matrix metalloproteinases. FEBS J. 2013, 280:2342-2352.
155. Song R.X., Barnes C.J., Zhang Z., Bao Y., Kumar R., Santen R.J. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:2076-2081.
156. Song R.X., Zhang Z., Chen Y., Bao Y., Santen R.J. Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology 2007, 148:4091-4101.
157. Song R.X., Chen Y., Zhang Z., Bao Y., Yue W., Wang J.P., Fan P., Santen R.J. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. J. Steroid Biochem. Mol. Biol. 2010, 118:219-230.
158. Stanley M.J., Stanley M.W., Sanderson R.D., Zera R. Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am. J. Clin. Pathol. 1999, 112:377-383.
159. Stigliano I., Puricelli L., Filmus J., Sogayar M.C., de Kier Bal, Joffe E., Peters M.G. Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation. Breast Cancer Res. Treat. 2009, 114:251-262.
160. Su G., Blaine S.A., Qiao D., Friedl A. Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation. J. Biol. Chem. 2007, 282:14906-14915.
161. Su G., Blaine S.A., Qiao D., Friedl A. Membrane type 1 matrix metalloproteinase-mediated stromal syndecan-1 shedding stimulates breast carcinoma cell proliferation. Cancer Res. 2008, 68:9558-9565.
162. Surmacz E., Bartucci M. Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer. J. Exp. Clin. Cancer Res. 2004, 23:385-394.
163. Syrokou A., Tzanakakis G., Tsegenidis T., Hjerpe A., Karamanos N.K. Effects of glycosaminoglycans on proliferation of epithelial and fibroblast human malignant mesothelioma cells: a structure-function relationship. Cell Prolif. 1999, 32:85-99.
164. Syrokou A., Tzanakakis G.N., Hjerpe A., Karamanos N.K. Proteoglycans in human malignant mesothelioma. Stimulation of their synthesis induced by epidermal, insulin and platelet-derived growth factors involves receptors with tyrosine kinase activity. Biochimie 1999, 81:733-744.
165. Tan J.X., Wang X.Y., Li H.Y., Su X.L., Wang L., Ran L., Zheng K., Ren G.S. HYAL1 overexpression is correlated with the malignant behavior of human breast cancer. Int. J. Cancer 2011, 128:1303-1315.
166. Tan J.X., Wang X.Y., Su X.L., Li H.Y., Shi Y., Wang L., Ren G.S. Upregulation of HYAL1 expression in breast cancer promoted tumor cell proliferation, migration, invasion and angiogenesis. PLoS One 2011, 6:e22836.
167. Theocharis A.D. Versican in health and disease. Connect. Tissue Res. 2008, 49:230-234.
168. Theocharis A.D., Seidel C., Borset M., Dobra K., Baykov V., Labropoulou V., Kanakis I., Dalas E., Karamanos N.K., Sundan A., Hjerpe A. Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro. J. Biol. Chem. 2006, 281:35116-35128.
169. Theocharis A.D., Skandalis S.S., Tzanakakis G.N., Karamanos N.K. Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J. 2010, 277:3904-3923.
170. Theocharis A., Gialeli C., Hascall V., Karamanos N. Extracellular matrix: a functional scaffold. Extracellular Matrix: Pathobiology and Signaling 2012, 3-20. De Gruyter, Berlin. N.K. Karamanos (Ed.).
171. Troup S., Njue C., Kliewer E.V., Parisien M., Roskelley C., Chakravarti S., Roughley P.J., Murphy L.C., Watson P.H. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin. Cancer Res. 2003, 9:207-214.
172. Tsonis A.I., Afratis N., Gialeli C., Ellina M.I., Piperigkou Z., Skandalis S.S., Theocharis A.D., Tzanakakis G.N., Karamanos N.K. Evaluation of the coordinated actions of estrogen receptors with epidermal growth factor receptor and insulin-like growth factor receptor in the expression of cell surface heparan sulfate proteoglycans and cell motility in breast cancer cells. FEBS J. 2013, 280:2248-2259.
173. Tzanakakis G.N., Karamanos N.K., Syrokou A., Hjerpe A. Effect of insulin and epidermal growth factors on the synthesis of glycosaminoglycans/proteoglycans in cultured human malignant mesothelioma cells of different phenotypic morphology. APMIS 1996, 104:718-728.
174. van Agthoven T., Timmermans M., Foekens J.A., Dorssers L.C., Henzen-Logmans S.C. Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry. Am. J. Pathol. 1994, 144:1238-1246.
175. Vuillermoz B., Khoruzhenko A., D'Onofrio M.F., Ramont L., Venteo L., Perreau C., Antonicelli F., Maquart F.X., Wegrowski Y. The small leucine-rich proteoglycan lumican inhibits melanoma progression. Exp. Cell Res. 2004, 296:294-306.
176. Wight T.N. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr. Opin. Cell Biol. 2002, 14:617-623.
177. Woodward T.L., Xie J., Fendrick J.L., Haslam S.Z. Proliferation of mouse mammary epithelial cells in vitro: interactions among epidermal growth factor, insulin-like growth factor I, ovarian hormones, and extracellular matrix proteins. Endocrinology 2000, 141:3578-3586.
178. Xiang Y.Y., Ladeda V., Filmus J. Glypican-3 expression is silenced in human breast cancer. Oncogene 2001, 20:7408-7412.
179. Yan P.S., Chen C.M., Shi H., Rahmatpanah F., Wei S.H., Caldwell C.W., Huang T.H. Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. Cancer Res. 2001, 61:8375-8380.
180. Yang N., Mosher R., Seo S., Beebe D., Friedl A. Syndecan-1 in breast cancer stroma fibroblasts regulates extracellular matrix fiber organization and carcinoma cell motility. Am. J. Pathol. 2011, 178:325-335.
181. Yang C., Cao M., Liu H., He Y., Xu J., Du Y., Liu Y., Wang W., Cui L., Hu J., Gao F. The high and low molecular weight forms of hyaluronan have distinct effects on CD44 clustering. J. Biol. Chem. 2012, 287:43094-43107.
182. Yee D., Lee A.V. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J. Mammary Gland Biol. Neoplasia 2000, 5:107-115.
183. Yee A.J., Akens M., Yang B.L., Finkelstein J., Zheng P.S., Deng Z., Yang B. The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. Breast Cancer Res. 2007, 9:R47.
184. Yenush L., White M.F. The IRS-signalling system during insulin and cytokine action. Bioessays 1997, 19:491-500.
185. Zeltz C., Brezillon S., Kapyla J., Eble J.A., Bobichon H., Terryn C., Perreau C., Franz C.M., Heino J., Maquart F.X., Wegrowski Y. Lumican inhibits cell migration through alpha2beta1 integrin. Exp. Cell Res. 2010, 316:2922-2931.
186. Zhang H., Hoff H., Sell C. Insulin-like growth factor I-mediated degradation of insulin receptor substrate-1 is inhibited by epidermal growth factor in prostate epithelial cells. J. Biol. Chem. 2000, 275:22558-22562.
187. Zhu J.X., Goldoni S., Bix G., Owens R.T., McQuillan D.J., Reed C.C., Iozzo R.V. Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis. J. Biol. Chem. 2005, 280:32468-32479.